Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, RP China.
Cardiovascular Research Institute of Wuhan University, Wuhan 430060, RP China.
Int J Biol Sci. 2020 Jul 2;16(13):2414-2429. doi: 10.7150/ijbs.47180. eCollection 2020.
Cardiac remodeling is a common characteristic of almost all forms of heart disease, including cardiac infarction, valvular diseases, hypertension, arrhythmia, dilated cardiomyopathy and other conditions. It is not merely a simple outcome induced by an increase in the workload of cardiomyocytes (CMs). The remodeling process is accompanied by abnormalities of cardiac structure as well as disturbance of cardiac function, and emerging evidence suggests that a wide range of cells in the heart participate in the initiation and development of cardiac remodeling. Other than CMs, there are numerous noncardiomyocytes (non-CMs) that regulate the process of cardiac remodeling, such as cardiac fibroblasts and immune cells (including macrophages, lymphocytes, neutrophils, and mast cells). In this review, we summarize recent knowledge regarding the definition and significant effects of various non-CMs in the pathogenesis of cardiac remodeling, with a particular emphasis on the involved signaling mechanisms. In addition, we discuss the properties of non-CMs, which serve as targets of many cardiovascular drugs that reduce adverse cardiac remodeling.
心脏重构是几乎所有类型心脏病的共同特征,包括心肌梗死、瓣膜病、高血压、心律失常、扩张型心肌病等。它不仅仅是心肌细胞(CM)工作量增加所导致的简单后果。重构过程伴随着心脏结构的异常和心脏功能的紊乱,新出现的证据表明,心脏中的多种细胞参与了心脏重构的启动和发展。除了 CM 之外,还有许多调节心脏重构过程的非心肌细胞(non-CMs),如心脏成纤维细胞和免疫细胞(包括巨噬细胞、淋巴细胞、中性粒细胞和肥大细胞)。在这篇综述中,我们总结了最近关于各种 non-CMs 在心脏重构发病机制中的定义和重要作用的知识,特别强调了涉及的信号机制。此外,我们还讨论了作为许多减少不良心脏重构的心血管药物靶点的 non-CMs 的特性。